Vericel Corporation (NASDAQ: VCEL), a leader in advanced cell therapies for sports medicine and severe burn care, reported its financial results for the first quarter ended March 31, 2026. Total revenue for Q1 2026 was $57.2 million, a 23% increase compared to $46.5 million in the same period of 2025.
The company raised its full-year 2026 revenue guidance to between $260 million and $270 million, up from the previous range of $250 million to $260 million. This revision reflects strong demand for its lead products, MACI (autologous cultured chondrocytes on porcine collagen membrane) for knee cartilage repair, and Epicel (cultured epidermal autografts) for severe burns.
Net income for Q1 2026 was $5.1 million, or $0.10 per diluted share, compared to a net loss of $2.3 million, or -$0.05 per diluted share, in Q1 2025. Adjusted EBITDA was $12.4 million, up from $4.8 million in the prior-year quarter.
Vericel ended the quarter with $145.6 million in cash, cash equivalents, and investments. The company also reiterated its commitment to expanding its product pipeline, including ongoing clinical trials for new indications.
